Cargando…

Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas

Alternative Lengthening of Telomeres (ALT) is a telomere maintenance pathway utilised in 15% of cancers. ALT cancers are strongly associated with inactivating mutations in ATRX; yet loss of ATRX alone is insufficient to trigger ALT, suggesting that additional cooperating factors are involved. We ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Udugama, M., Hii, L., Garvie, A., Cervini, M., Vinod, B., Chan, F.-L., Das, P. P., Mann, J. R., Collas, P., Voon, H. P. J., Wong, L. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110556/ https://www.ncbi.nlm.nih.gov/pubmed/33972520 http://dx.doi.org/10.1038/s41467-021-22543-z

Ejemplares similares

Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers
por: Udugama, Maheshi, et al.
Publicado: (2018)

Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma
por: Voon, Hsiao P. J., et al.
Publicado: (2018)

Histone H3.3 phosphorylation promotes heterochromatin formation by inhibiting H3K9/K36 histone demethylase
por: Udugama, Maheshi, et al.
Publicado: (2022)

The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype
por: Amorim, João P., et al.
Publicado: (2016)

ATRX/DAXX: Guarding the Genome against the Hazards of ALT
por: Clatterbuck Soper, Sarah F., et al.
Publicado: (2023)

Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023)

Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants
por: Stundon, Jennifer L, et al.
Publicado: (2022)

Significance of TERT and ATRX mutations in glioma
por: Liu, Jiayu, et al.
Publicado: (2019)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

CHK1-driven histone H3.3 serine 31 phosphorylation is important for chromatin maintenance and cell survival in human ALT cancer cells
por: Chang, Fiona T. M., et al.
Publicado: (2015)

New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone
por: Voon, Hsiao P.J., et al.
Publicado: (2016)

Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX
por: Hu, Yang, et al.
Publicado: (2016)

TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

Choroidal melanoma with synchronous Fuchs’ adenoma and novel ATRX mutation
por: Harford, Elli, et al.
Publicado: (2022)

Whole exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas
por: Fishbein, Lauren, et al.
Publicado: (2015)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?
por: Marinoni, Ilaria
Publicado: (2022)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations
por: Casar-Borota, Olivera, et al.
Publicado: (2020)

Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors
por: Yuan, Ming, et al.
Publicado: (2022)

Formal reply to “Alternative lengthening of telomeres is not synonymous with mutations in ATRX/DAXX”
por: Feuerbach, Lars
Publicado: (2021)

ATRX mutation in two adult brothers with non-specific moderate intellectual disability identified by exome sequencing()
por: Moncini, S., et al.
Publicado: (2013)

Telomere clustering drives ALT
por: Min, Jaewon, et al.
Publicado: (2019)

A novel exomal ATRX mutation with preferential transmission to offspring: A case report and review of the literature for transmission ratio distortion in ATRX families
por: Stabile, Mariano, et al.
Publicado: (2020)

The Role of ATRX in Glioma Biology
por: Nandakumar, Pravanya, et al.
Publicado: (2017)

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
por: Jiao, Yuchen, et al.
Publicado: (2012)

Two Novel Variants in the ATRX Gene Associated with Variable Phenotypes
por: Hettiarachchi, D., et al.
Publicado: (2019)

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
por: Brosnan-Cashman, Jacqueline A., et al.
Publicado: (2018)

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas
por: Leeper, Heather E., et al.
Publicado: (2015)

Chromatin mutations in pediatric high grade gliomas
por: Voon, Hsiao P. J., et al.
Publicado: (2023)

ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes
por: Voon, Hsiao P.J., et al.
Publicado: (2015)

Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size
por: Hackeng, Wenzel M, et al.
Publicado: (2022)

Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
por: Kannan, Kasthuri, et al.
Publicado: (2012)

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12
por: Mäkinen, Netta, et al.
Publicado: (2016)

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma
por: Wang, Yuxiang, et al.
Publicado: (2019)

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling
por: Danussi, Carla, et al.
Publicado: (2018)

The origin-of-cell harboring cancer-driving mutations in human glioblastoma
por: Lee, Joo Ho, et al.
Publicado: (2018)

Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
por: Chaurasia, Ajay, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b6boaihi8qcjm0ir59v2dqr1bj